INTRODUCTION: The aims of the study were to explore the levels of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in patients with benign, borderline, or malignant epithelial ovarian tumors and to compare them to those of healthy controls. In addition, we aimed to study how Ang-1 and Ang-2 levels predict the clinical course and survival of patients with epithelial ovarian cancer. METHODS: We enrolled 150 patients with ovarian neoplasms and 34 women with healthy ovaries in this study. Furthermore, we measured the levels of Ang-1 and Ang-2 in patients having an ovarian metastasis or another cancer (n = 29). Serum samples were collected preoperatively at the time of diagnosis, and Ang-1 and Ang-2 levels were measured with an enzyme-linked immunosorbent assay. RESULTS: Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P < 0.0005, respectively). In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011). In receiver operating characteristic analysis, the area under the curve for serum Ang-2 (0.77) was greater than Ang-1 (0.60) but lower than for cancer antigen 125 (0.95) to differentiate ovarian cancer from healthy control. High serum levels of Ang-1 and Ang-2 were associated with primary residual tumor more than 1 cm after debulking surgery, and high Ang-2 levels correlated positively with an advanced tumor stage (P = 0.042). Elevated Ang-2 level (>2.7 ng/mL) was a significant predictor of poor overall and recurrence-free survival (P = 0.043 and P = 0.033, respectively) when assessing Kaplan-Meier curves by a log-rank test. CONCLUSIONS: Patients with ovarian cancer have higher serum levels of angiopoietins than patients with benign or borderline tumors reflecting the increased angiogenesis. These results also suggest that Ang-2 may serve as an angiogenic marker of decreased patient survival in ovarian cancer.
INTRODUCTION: The aims of the study were to explore the levels of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in patients with benign, borderline, or malignant epithelial ovarian tumors and to compare them to those of healthy controls. In addition, we aimed to study how Ang-1 and Ang-2 levels predict the clinical course and survival of patients with epithelial ovarian cancer. METHODS: We enrolled 150 patients with ovarian neoplasms and 34 women with healthy ovaries in this study. Furthermore, we measured the levels of Ang-1 and Ang-2 in patients having an ovarian metastasis or another cancer (n = 29). Serum samples were collected preoperatively at the time of diagnosis, and Ang-1 and Ang-2 levels were measured with an enzyme-linked immunosorbent assay. RESULTS:Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P < 0.0005, respectively). In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011). In receiver operating characteristic analysis, the area under the curve for serum Ang-2 (0.77) was greater than Ang-1 (0.60) but lower than for cancer antigen 125 (0.95) to differentiate ovarian cancer from healthy control. High serum levels of Ang-1 and Ang-2 were associated with primary residual tumor more than 1 cm after debulking surgery, and high Ang-2 levels correlated positively with an advanced tumor stage (P = 0.042). Elevated Ang-2 level (>2.7 ng/mL) was a significant predictor of poor overall and recurrence-free survival (P = 0.043 and P = 0.033, respectively) when assessing Kaplan-Meier curves by a log-rank test. CONCLUSIONS:Patients with ovarian cancer have higher serum levels of angiopoietins than patients with benign or borderline tumors reflecting the increased angiogenesis. These results also suggest that Ang-2 may serve as an angiogenic marker of decreased patient survival in ovarian cancer.
Authors: Sandra P D' Angelo; Michelle R Mahoney; Brian A Van Tine; Douglas R Adkins; Maria T Grosse Perdekamp; Mercedes M Condy; Jason J Luke; Eliza Woodward Hartley; Cristina R Antonescu; William D Tap; Gary K Schwartz Journal: Cancer Chemother Pharmacol Date: 2015-02-12 Impact factor: 3.333
Authors: Gregory D Conway; Marguerite S Buzza; Erik W Martin; Nadire Duru; Tierra A Johnson; Raymond J Peroutka; Nisha R Pawar; Toni M Antalis Journal: J Mol Med (Berl) Date: 2019-03-25 Impact factor: 4.599
Authors: Dirk O Bauerschlag; Felix Hilpert; Werner Meier; Jörn Rau; Ivo Meinhold-Heerlein; Nicolai Maass; Andreas Dubois; Jalid Sehouli; Norbert Arnold; Christian Schem; Hans-Heinrich Oberg; Klaus Baumann Journal: Transl Oncol Date: 2013-06-01 Impact factor: 4.243
Authors: Angeles Alvarez Secord; Kirsten Bell Burdett; Kouros Owzar; David Tritchler; Alexander B Sibley; Yingmiao Liu; Mark D Starr; J Chris Brady; Heather A Lankes; Herbert I Hurwitz; Robert S Mannel; Krishnansu S Tewari; David M O'Malley; Heidi Gray; Jamie N Bakkum-Gamez; Keiichi Fujiwara; Matthew Boente; Wei Deng; Robert A Burger; Michael J Birrer; Andrew B Nixon Journal: Clin Cancer Res Date: 2020-01-09 Impact factor: 12.531